Takeda, Affymax Start Phase-3 Trials for Anemia Drug (Japan)
This article was originally published in PharmAsia News
Phase 3 clinical trials have commenced for Hematide, an anemia drug produced by Takeda Pharmaceutical Co. and Affymax Inc. The clinical trials will gauge the effectiveness of the drug in approximately 2,200 patients with chronic renal failure. The companies hope the drug will win approval in the United States and Europe by the end of the decade. (Click here for more - May Require Paid Subscription
You may also be interested in...
The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.